ACIU (AC Immune SA) stock: $2.63, $267.7M market cap, $33.8M cash, $233.9M EV, $296.0M fully diluted market cap. Next expected readout: Nov-26. Lead program: ACI-7104 (Parkinson Disease), Phase 2. Data from Fully Diluted's biotech stocks database.
Pipeline assets
ACI-35.030
Stage not disclosed · Active Modality: active immunotherapy
Target pTau (phosphorylated Tau)
Status note Described as a clinical product candidate; FDA Fast Track designation. The filing states no per-asset phase, indication, or target.
ACI-24.060
Stage not disclosed · Active Modality: active immunotherapy
Target Abeta (amyloid-beta)
Indications- Amyloid Plaque (Phase 2)
- Beta-Amyloid (Phase 2)
- DSAD (Phase 2)
Status note Described as a clinical product candidate; FDA Fast Track designation. The filing states no per-asset phase, indication, or target.
ACI-7104.056
Stage not disclosed · Active Modality: active immunotherapy
Target alpha-synuclein
Indications- Parkinson's disease (PD) (Stage not disclosed)
Status note Described as a clinically-validated active immunotherapy candidate targeting alpha-synuclein for Parkinson's disease, acquired via the 2021 Affiris portfolio purchase. The filing states no per-asset phase.
ACI-19764
Stage not disclosed · Active Modality: small molecule
Target NLRP3
Indications- Obesity (Phase 1)
- Type 2 Diabetes Mellitus (T2DM) (Phase 1)
Status note Described as an NLRP3 inhibitor small molecule drug program, retained after the September 2025 restructuring. The filing states no per-asset phase or indication.
Morphomer Tau
Preclinical · Active Modality: small molecule
Target tau
Status note Described as a small molecule drug program retained after the September 2025 restructuring; no clinical data stated.
Morphomer-a-syn
Preclinical · Active Modality: small molecule
Target alpha-synuclein
Status note Described as a small molecule drug program retained after the September 2025 restructuring; no clinical data stated.
PI-2620
Stage not disclosed · Active Modality: PET tracer diagnostic
Target tau
Status note Described as a Tau-PET tracer clinical product candidate; FDA Fast Track designation. No per-asset phase stated.
ACI-12589
Stage not disclosed · Active Modality: PET tracer diagnostic
Target alpha-synuclein
Status note Described as an alpha-synuclein PET tracer clinical product candidate. No per-asset phase stated.
ACI-15916
Stage not disclosed · Active Modality: PET tracer diagnostic
Target alpha-synuclein
Status note Described as an alpha-synuclein PET tracer clinical product candidate. No per-asset phase stated.
ACI-19626
Stage not disclosed · Active Modality: PET tracer diagnostic
Target TDP-43
Status note Described as a TDP-43-PET tracer clinical product candidate. No per-asset phase stated.
Per-asset detail extracted from the 20-F filed 2026-03-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.